TraceLink Inc., a North Reading, MA-based provider of information-sharing network platform across Life Sciences, closed a $93m funding round.
The round, which brought total funding to $167m, was led by Georgian Partners, with participation from Vulcan Capital and Willett Advisors LLC, and existing investors FirstMark Capital, Volition Capital, F-Prime Capital and Goldman Sachs. In conjunction with the funding, Tyson Baber from Georgian Partners joined TraceLink’s Board of Directors.
The company intends to use the funds:
– to accelerate the digitalization of the global pharmaceutical supply chain through the integration of real-time information-sharing,
– to expand into adjacent application areas, such as supplier collaboration, patient communities, personalized medicine, predictive care and gene therapies, – to further reinforce its R&D and Services organizations to support its customer base of 930+ pharmaceutical manufacturers, contract manufacturers (CMO), wholesaler distributors, third party logistic providers (3PL), hospitals and pharmacies.
Founded in 2009 and led by Shabbir Dahod, president and CEO, TraceLink is a track and trace network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes.
The company’s network connects over 270,000 pharmaceutical companies, CMOs, wholesale distributors, 3PLs, parallel importers, repackagers, hospitals and pharmacies worldwide.